CytoSorbents highlights new sepsis studies showing improved survival with early, intensive CytoSorb use

Cytosorbents Corp

Meta-analysis of 744 septic shock patients: CytoSorb reduced in-hospital mortality (OR 0.64, p=0.036) and halved 28–30 day mortality (OR 0.46, p=0.003).
Berlot et al. study of 175 patients: early intensive CytoSorb use (≥3 cartridges in 2–3 days) nearly doubled survival (70% observed vs 37% predicted).
100-patient U.S. COVID-19 registry on ECMO: 74% 90-day survival, rising to 82% with early treatment, outperforming ~50% benchmarks.
Company to host World Sepsis Day Global Webinar on September 10, 2025 to discuss CytoSorb best practices.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.